TherapeuticsMD (TXMD) Net Equity Issued and Repurchased (2012 - 2023)

TherapeuticsMD (TXMD) posted Net Equity Issued and Repurchased of $2.0 million for Q4 2023, up 200300.0% on a QoQ basis from -$1000.0 in Q3 2023.

TherapeuticsMD (TXMD) Net Equity Issued and Repurchased (2012 - 2023) Analysis & Trends

TherapeuticsMD's Net Equity Issued and Repurchased history runs 6 years deep, the most recent figure standing at $2.0 million for Q4 2023.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $2.0 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $3.2 million (down 90.26% YoY) and the FY2023 annual result came in at $3.2 million, up 28.4% from the prior year.
Net Equity Issued and Repurchased was $2.0 million for Q4 2023 at TherapeuticsMD, up from -$1000.0 in the prior quarter.
Across five years, Net Equity Issued and Repurchased topped out at $150.9 million in Q1 2021 and bottomed at -$1000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	-
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	-
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	-
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	-
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	500,000.00
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	23.60 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	-
10	TherapeuticsMD	280,159.99	-8.14 Mn	-	-

Download Data